Breakthroughs put the bite on malaria. by Tenenbaum, David J
H
alf a century ago, a potent com-
bination of antibiotics, vaccines,
and public health measures
seemed poised to win the ancient war
against infectious disease. Even malaria
appeared to be succumbing to a mix of
insecticides, larvicides (used to kill the
mosquito vector), and drugs (used to kill
the malaria-causing Plasmodium parasite in
the human bloodstream). But while small-
pox and polio were conquered, malaria was
not; mosquito evolution and concerns
about health effects from insecticides
blunted mosquito eradication campaigns,
and Plasmodium developed resistance to
many drugs. Today, malaria is resur-
gent in many tropical regions, espe-
cially Africa. According to the
World Health Organization, each
year it infects more than 300
million people and kills at least
1 million, mostly children. 
In the last year, however, major
progress has been reported in basic
research on malaria. One research
group has reported a genetic manip-
ulation that impairs the mosquito’s
ability to transmit the malaria para-
site. Another has reported progress
toward a vaccine that targets a newly
discovered toxin made by Plas-
modium. And this October, prelimi-
nary genomes were reported for the
major malaria parasite, P. falci-
parum, and the major vector, the
Anopheles gambiae mosquito.
An Antimalarial Mosquito 
Human malaria is caused by four
members of the genus Plasmodium,
which goes through a complex life
cycle. After a person is bitten by an
infected mosquito, the parasite mul-
tiplies for a few days in the liver, and then
is distributed through the blood. When
other mosquitoes take a “blood meal”
from an infected person, the parasite sexu-
ally reproduces in the mosquito’s gut. The
parasite leaves the gut and reaches the sali-
vary glands, at which point the mosquito
is poised to infect another person.
The first symptoms of malaria start
when Plasmodium enters the blood, when
the characteristic “paroxysms”—cycles of
fevers and chills—begin. Malaria may also
cause renal or pulmonary failure; cerebral
malaria, which usually afflicts children and
pregnant women, can cause coma, gener-
alized convulsions, and death.
Whereas malaria fighters have histori-
cally attacked the parasite or the vector,
other targets are emerging from the study
of the complicated interaction of parasite,
vector, host, and environment. Many
mosquito species, for example, are resis-
tant to infection with Plasmodium. Could
that resistance be transferred to those that
do transmit malaria? In the 23 May 2002
issue of Nature, Marcelo Jacobs-Lorena, a
professor of genetics at Case Western
Reserve University, and colleagues report-
ed on a major advance toward answering
that question—they genetically engineered
a strain of mosquito with an impaired
ability to spread a rodent malaria parasite.
The researchers focused on receptor
molecules on the epithelium of the mos-
quito gut. During the ookinete life stage,
the parasite links to these receptors as it
migrates to the salivary glands. The
researchers made about 1 billion artificial
peptides and found one that bonded to
the gut’s lining, blocking receptors there.
Because the blood meal is the point at
which the mosquito becomes infected
with Plasmodium, any gene activated when
the blood is digested could possibly also
be pressed into service as a malaria fighter.
So the team inserted a gene for this pep-
tide into the mosquito genome, and
instructed the genome to activate
the gene after the mosquito took a
blood meal. 
Only two of the three groups of
modified mosquitoes actually failed
to transmit malaria, says Jacobs-
Lorena. He adds that the peptide is
not 100% effective; there are always
escapees. “That’s one of many rea-
sons why this is just a first step in the
right direction,” he says. Still, the
experiments reported in Nature were
proof in principle that it’s possible to
block the spread of malaria, he says. 
Many questions about this appli-
cation of transgenic technology
remain to be answered. One con-
cerns testing efficacy and safety.
Bruce Christensen, a professor of
animal health and biomedical sci-
ences who studies the interaction of
malaria parasites and mosquito vec-
tors at the University of Wisconsin at
Madison, says, “It’s extremely diffi-
cult . . . to see how the variety of dif-
ferent [parasite] genotypes respond
in the engineered mosquito.
Whenever you are dealing with a
pathogen–host relationship, it’s a two-way
street. The presence of one influences the
gene expression in the other. . . . To thor-
oughly understand the relationship is bru-
tally difficult research to do.”
The malaria-resistant mosquitoes must
also outcompete normal malaria-vectoring
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Targeting a toxin. A new malaria vaccine targets a compound
made by Plasmodium that may be the source of malarial pathology.
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Bite onMalariamosquitoes—they must be more geneti-
cally fit. Richard Carter, a professorial fel-
low in the Division of Biological Sciences
at Scotland’s University of Edinburgh,
says the effect on fitness depends upon the
specific genetic modification involved. In
the case of Jacobs-Lorena’s work, he says,
“the modification might have some
chance of becoming established in wild
mosquito populations if it carries very lit-
tle intrinsic cost to the mosquitoes [and]
otherwise makes them healthier, because,
unlike wild mosquitoes, they do not risk
becoming infected with malaria.”
However, Carter admits that research on
whether freedom from malarial infection
can be expected to cause
mosquitoes to live longer
or reproduce better has
produced “rather a mixed
bag of results.”
Any antimalaria strate-
gy must survive the para-
site’s proven ability to
evolve and thus evade con-
trol strategies. In this
respect, Carter thinks
Jacobs-Lorena’s technique
has an advantage. “At [the
ookinete] point in their
life cycle, the parasites are
not in fact increasing in
numbers, but decreasing,”
he says. “Two gametes
form a zygote—one cell
from two—and the zy-
gotes of malaria parasites
do not multiply in the
midgut. Thus, in terms of
the possibility of selection,
we are talking tiny numbers; only one to
a few dozen zygotes are destined to sur-
vive to form oocysts in a single mosquito
under any circumstances.” 
Conversely, he says, conventional
malaria drugs attack billions to trillions of
parasites that are multiplying in the human
bloodstream, which he calls a “classic situa-
tion for selecting for resistant microorgan-
isms.” Because a much smaller number of
nonmultiplying parasites exists in the mos-
quito’s gut, he says, “the selection pressure
is orders of magnitude smaller.”
However, numerous practical obstacles
remain before a successful release of genet-
ically modified mosquitoes can be expect-
ed. Carter observes, for example, that
modified insects have generally failed to
control disease. The sole exception was a
campaign against the screwworm, a cattle
pest in the southern United States, in
which the release of millions of sterile
adult male screwworm flies caused massive
breeding failure among the pest. The
screwworm was declared eradicated from
the United States in 1966.
The environmental impact would also
need careful study, according to a group
of ecologists who discussed the matter in
the 5 July 2002 issue of Science. Politics
and public education are major areas of con-
cern. For example, people who have been
told to protect themselves against mosqui-
toes might well question the release of
millions of addi-
tional mosquitoes.
Christensen notes
that a mosquito-
control project
designed to release millions of sterile
male mosquitoes in India several decades
ago infuriated the intended beneficiaries:
“People burned the trucks and chased the
public health officials away.”
Aggravating the situation would be
the fact that the mosquitoes would be
genetically engineered. Recalling the
recent uproar in Zambia over the safety
of genetically engineered corn donated
to feed starving people, Joseph Vinetz,
am alaria researcher who is an assistant
professor in the Center for Tropical
Medicine at the University of Texas
Medical Branch in Galveston, asks, “If we
could release an environmentally friendly
mosquito that is refractory to malaria,
who is going to believe it’s harmless?”
Still, Vinetz argues, solutions to
malaria must be judged according to the
severity of the problem. “Malaria is one
of the most important problems in the
entire world,” he says. “Therefore, the
threshold for doing something [to address
it] should be lower than for dealing with
something less important.” 
Vaccine Technology 
The year 2002 also saw progress toward
a novel malaria vaccine technology,
described in the 15 August 2002 issue of
Nature. In contrast to most existing vac-
cines, the new vaccine targets not proteins
on the pathogen’s exterior but rather a
compound called
glycosylphos-
phatidylinositol
(GPI) that seems
to cause malaria’s
most deadly symp-
toms—and may
be a long-sought
malaria toxin. Antitoxin vac-
cines are effective against
tetanus and diphtheria.
The research grew
from frustration with the
conventional approach to
malaria vaccines, says
Louis Schofield, first
author of the August
Nature paper. Schofield, a
researcher at the Walter
and Eliza Hall Institute of
Medical Research in
Melbourne, Australia, says
that when he did his
Ph.D. work in the 1980s,
“there was great enthusi-
asm for developing a
malaria vaccine, and the
whole world was busy
cloning parasite surface
proteins.” Schofield, however, worried
that proteins that did not interact with
the human host would be susceptible to
the Achilles’ heel of malaria vaccines—
the genetic variability of the pathogen. In
other words, if such proteins were not
intimately involved in the disease process,
they would not be conserved by evolu-
tion, and thus might be so variable as to
be useless as drug targets.
Instead, Schofield was intrigued by
GPI. Various GPIs, Schofield says, tether
proteins to the cell surface in all multi-
celled organisms. Schofield found that
Plasmodium GPI was associated with a
complex lipid known as diacylglycerol, a
molecule that regulates a variety of cellular
functions and is known to activate protein
kinase C. He also found that Plasmodium
GPI would hyperactivate macrophages
and antigen-presenting cells in the
immune system, and cause red blood cells
to adhere to blood vessels—all conditions
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You know by the glow. Mosquitoes that have been genetically manipulated to
impair their ability to transmit malaria glow with a fluorescent green marker (inset:
right; large picture: top and bottom).
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“At last we had a parasite molecule that
could possibly cause the widespread host
cell activation that causes pathology in
malaria,” he says.
GPI, in other words, looked like a toxin.
Schofield spent years examining whether
this was actually the case in cell culture and
animal research, but too little of the com-
pound was available to really test the propo-
sition. Eventually, Peter Seeberger, a
chemist at the Massachusetts Institute of
Technology, synthesized a larger quantity of
pure Plasmodium GPI, which was used in
the experiment reported this year in Nature.
“[Schofield] had a feeling that it might be
the toxin for a long time,” says Seeberger,
“but if you purify such a tiny amount, you
can’t characterize it. An impurity may be
responsible for the toxicity.”
When Schofield and colleagues vacci-
nated mice with the pure, synthesized
Plasmodium GPI, it prevented most of the
symptoms of cerebral malaria and reduced
acidosis (elevated blood acidity), a condi-
tion closely linked to mortality in malaria.
The GPI vaccine works by stimulating
the production of antibodies that, as
Schofield puts it, “latch on to the toxin
and inactivate it.” 
As the vaccine work moves toward ani-
mal efficacy and toxicity research, several
questions remain open. Although malaria
eventually killed the experimental mice,
Schofield attributes that to a massive
growth of the parasite that occurs in mice
but not in humans, and thus he thinks it
should not be a cause for concern. Another
unknown is how long the antibody will
continue to neutralize the toxin. “I don’t
think any antibody–antigen bond is irre-
versible,” Schofield says, “but if [it lasts]
sufficiently long to block the action of the
toxin, that’s long enough.”
A more basic uncertainty concerns the
status of GPI. Is it the principal malaria
toxin? The only one? “Schofield was very
careful about this,” says Thomas Richie,
director of malaria clinical trials at the
Naval Medical Research Center in Silver
Spring, Maryland. “Plasmodium is a com-
plex parasite, and in general, many of its
key interactions with the host may be
mediated by more than one molecule.
What we have learned about the patho-
physiology of severe malaria in humans
suggests that GPI by itself is unlikely to be
the sole mediator of clinical illness.” Still,
in a research field that’s perennially short
on good news, Richie says the GPI vaccine
is “a great development.” 
Genomes Galore
In October, two large international
collaborations marked milestones in the
war against malaria: publication of the
genome for P. falciparum in the 3 October
2002 issue of Nature and the genome for
A. gambiae in the 4 October 2002 issue
of Science. The research reports, together
with numerous associated articles,
describe the genomes and suggest how
the new information might be used to
control malaria.
The mosquito genome, described by a
group under the leadership of Robert Holt
of Celera Genomics in Rockville,
Maryland, contains 278 million base
pairs—about 10% as large as the human
genome. In addition to publishing the
DNA sequence, Holt’s group focused on a
topic of considerable interest among
malaria researchers: the genetic effects of
the mosquito’s blood meal. While the
female is digesting mammalian blood,
genes for protein and lipid metabolism are
up-regulated, while genes for muscular
and sensory activities are down-regulated.
Knowledge of the mosquito genome
may change the way insecticides are devel-
oped. Rather than testing them against the
whole insect, they may be tested against
gene products. Indeed, Holt says develop-
ment of insecticides and vaccines may be
the most important first results of the
genome work: “I think the most important
thing the genome will facilitate in the
immediate future is understanding the
molecular basis for resistance to insecticides
and finding new insecticide targets.”
Another avenue for study would be to
genetically engineer the mosquito so it
would be less attracted to humans as a
source of blood.
With significant scientific synchrony,
Malcolm Gardner of the Institute for
Genomic Research in Rockville and col-
leagues published the P. falciparum genome
the same week. The sequencing team tenta-
tively identified 5,279 genes, but said the
function of 60% were unknown. The para-
site is genetically distinct from all previous-
ly sequenced organisms, which makes the
task of taking advantage of the genome
more difficult.
Russell Doolittle, a research professor
with the Center for Molecular Genetics at
the University of California at San Diego,
observes that the parasite genome offers
“almost too many options to pursue” in
terms of new targets for drug treatment.
One group of targets identified by the
genome authors were protein-degrading
enzymes found in a subcellular digestive
component called the food vacuole. These
enzymes are involved in digestion of the
blood meal.
However, Doolittle also warned in a
commentary in the 3 October 2002
Nature that the genomes may promise
more than they can deliver in terms of
actually reducing the burden of disease.
Noting a continual tension between on-
the-ground measures to control malaria
(such as bed nets and larvicide spraying)
and high-tech approaches (such as vaccines
and malaria-resistant mosquitoes), he
asked, “So is it worth it from a medical
point of view? That really remains to be
seen.” Whole-genome projects, he wrote,
have delivered more to basic biology than
to medicine; for the most part, the
promised medical benefits have been slow
to materialize.
It’s impossible to say whether or when
these advances against malaria will bear
fruit by reducing the burden of disease. But
malaria researchers already know from long
experience that their enemy is devious and
resourceful, and the dominant sentiment in
the field seems to be a preference for hedg-
ing bets. Jacobs-Lorena, for example, says,
“I can’t imagine that the transgenic mos-
quito would be one hundred percent effec-
tive. There’s a strong consensus in the field
that only a combination of approaches will
really work to solve the problem.”
David J. Tenenbaum
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